Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

N1087

Phase 3Small molecule

EEurofarma Laboratorios S.A.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Female Pattern Hair LossNot yet recruiting

Female Pattern Hair LossPhase 3

Not yet recruiting

Timeline

Expected Milestones

Q3 2028

Phase 3Not yet recruiting

Female Pattern Hair Loss

NCT07303322

Clinical

Trials by Indication[1]

Female Pattern Hair Loss1 trial

Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Participants With Female Pattern Hair Loss (MINORA-WOMEN)

Not yet recruiting·EEurofarma Laboratorios S.A.·Phase 3·NCT07303322·372 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for N1087. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — N1087 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for N1087. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eurofarma Laboratorios S.A. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEurofarma Laboratorios S.A.

Related News